Global Cancer Tumor Profiling Market - 2025 -2033
Cancer Tumor Profiling Market Size
The global cancer tumor profiling market size reached US$ 10.98 Billion in 2024 from US$ 10.12 Billion in 2023 and is expected to reach US$ 24.62 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.
Cancer Tumor Profiling Market Overview
The cancer tumor profiling market is experiencing significant growth due to advancements in precision medicine, increasing cancer prevalence and the rising demand for personalized treatment approaches. Cancer tumor profiling has revolutionized cancer care by improving diagnosis, treatment efficacy, monitoring and helping to predict patient outcomes.
The market is characterized by strong demand in developed regions, such as North America and Europe, driven by higher healthcare expenditure, advanced healthcare infrastructure and greater adoption of precision medicine. Meanwhile, emerging regions such as Asia-Pacific and Latin America are experiencing increasing adoption of cancer tumor profiling, spurred by growing healthcare investments, increasing cancer rates and expanding awareness about personalized treatment options.
Cancer Tumor Profiling Market Dynamics
Drivers:
The rising prevalence of cancer is significantly driving the cancer tumor profiling market growth
As cancer rates rise globally, there is a growing emphasis on early detection and personalized medicine. Tumor profiling helps identify specific genetic mutations and alterations in tumors, which enables more accurate diagnoses and the development of personalized treatment plans. This helps in providing targeted therapies that are more effective and less toxic than traditional treatments.
For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Additionally, according to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.
Breast cancer is becoming the most burdensome cancer in the world, with an alarming rise in incidence and prevalence rate. There have been many innovations in the early detection and diagnosis of breast cancer, for which advanced tumor profiling technologies are paving the way. For instance, according to the International Agency for Research on Cancer projections, nearly 2.7 million breast cancer incidence cases are expected to be reported in 2030, rising from 2.3 million in 2022.
As the prevalence of cancer increases, major market players focus on the advancements in next-generation sequencing (NGS) and liquid biopsy technologies that are providing better and more efficient tumor profiling. These advanced technologies, along with artificial intelligence (AI), enable high-throughput testing of genetic mutations in cancer cells, leading to more precise treatment selection.
For instance, in April 2025, Guardant Health, Inc. launched Guardant360 Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, to provide researchers and cancer care teams with a more comprehensive view of cancer. Guardant360 Tissue is built on the smart liquid biopsy platform, which requires 92% less tissue surface area for analysis than the industry norm. The Guardant360 Tissue test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides and thus test more patients using less precious tissue.
Restraints:
The high cost associated with cancer tumor profiling is hampering the growth of the market
High costs make tumor profiling tests inaccessible to a large portion of the population, particularly in low-income regions or among uninsured patients. This limits the potential market for these tests and delays early detection or personalized treatment, which is crucial for improving cancer outcomes.
For instance, according to the National Institutes of Health, turnaround time ranges from 4 days for Oncomine Dx, a 23-gene panel of lung-cancer-related genes, to 21 to 28 days for Ambry Genetics TumorNext, which examines hereditary and somatic mutations in ovarian cancer patients. Costs for testing are in the $3000 to $6000 range. This price point can be prohibitive for many patients, especially those without adequate insurance coverage.
Laboratories that perform tumor profiling using advanced technologies like NGS face high operational costs due to the expensive equipment, consumables and the need for highly skilled personnel. These costs are passed on to healthcare systems and patients, making tumor profiling tests less affordable. For instance, the cost of sequencing equipment for NGS, which includes instruments like the Illumina NovaSeq X Plus, can exceed $1 million. Additionally, reagents and consumables for each test add significant costs to the overall process.
Opportunities:
Integration of artificial intelligence (AI) in tumor profiling creates a market opportunity for the cancer tumor profiling market
Integration of AI in tumor profiling is expected to create a market opportunity for the cancer tumor profiling market, driving advancements in diagnostic accuracy, speed and personalized treatment strategies. AI technologies, including machine learning (ML), deep learning and natural language processing, are transforming the way cancer tumor profiling is conducted by enabling more efficient and precise analyses of large datasets, such as genomic information and medical imaging. Thus, major and emerging market players are focusing on the AI-tumor profiling, gaining market momentum.
For instance, in January 2025, Tempus AI, Inc. launched the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
AI algorithms can process vast amounts of genomic, histopathological and imaging data in a fraction of the time it would take human analysts, reducing errors and ensuring higher diagnostic accuracy. This can significantly improve the effectiveness of tumor profiling, enabling more accurate predictions of cancer behavior and treatment responses.
For instance, New York-based medtech startup Ataraxis AI has emerged from stealth mode, announced $4 million in seed funding. The company has a focus on developing artificial intelligence (AI) driven cancer diagnostics that can help clinicians to pick the best therapy for their patients and predict their progress.
AI-driven platforms can serve as a clinical decision support system, assisting oncologists in interpreting complex tumor profiling results, such as genetic mutations and tumor characteristics. This can lead to more informed clinical decisions and help in identifying optimal treatment paths based on real-time data integration, including genetic profiling, clinical outcomes and patient demographics
Cancer Tumor Profiling Market, Segment Analysis
The global cancer tumor profiling market is segmented based on product type, cancer type, technology type, biomarker type, application, end-user, and region.
The kits and consumables segment from the product type reached US$ 10.11 Billion in 2024 in the cancer tumor profiling market
Kits and consumables include laboratory materials necessary for the execution of tests related to cancer profiling, which could be assay kits, probes, primers, and reagents. These products are necessary for the preparation, processing, and analysis of different tumor samples, whether genomic, proteomic, or metabolomic studies. As the kits are more important products in tumor profiling, market players are launching various kits, which is driving the segment growth.
For instance, in May 2025, Illumina, Inc. received approval from the Ministry of Health, Labour and Welfare (MHLW) for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device) in Japan. TSO Comprehensive is the first FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims in the US. This single test includes analysis of DNA and RNA variants and interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying clinically actionable biomarkers that enable targeted therapy selection or clinical trial enrolment.
Similarly, in October 2024, OncoDNA, a genomic and theranostic company, launched the OncoDEEP Kit, a comprehensive workflow solution for laboratories with NGS capabilities to perform comprehensive biomarker testing, provide powerful data analysis, and support oncologists in personalized treatments for cancer patients.
Cancer Tumor Profiling Market, Geographical Analysis
North America is expected to dominate the global cancer tumor profiling market with a US$ 5.24 Billion in 2024
According to the American Cancer Society, in 2025, 2,041,910 new cancer cases are projected to occur in the United States. The rising cancer cases in North America, especially in the United States, drive demand for personalized treatment strategies, pushing the adoption of tumor profiling to tailor therapies and improve outcomes.
Additionally, although the market is dominant, several market players are actively involved in innovating advanced tumor profiling platforms and launching their products in the region. This will contribute to the further growth of the cancer tumor profiling market in the North American region. For instance, in August 2024, the U.S. Food and Drug Administration (FDA) approved Illumina, Inc.’s in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic indications. This test enables fast matching of patients to targeted therapies.
Asia-Pacific is growing at the fastest pace in the cancer tumor profiling market, holding 18.05% of the market share
APAC is experiencing a rapid increase in cancer cases due to aging populations, urbanization, lifestyle changes, and environmental factors. According to the World Health Organization (WHO), Asia accounts for more than half of global cancer cases, with an expected 10.5 million cases in 2025, with countries like China and India seeing significant year-on-year increases. This escalating cancer burden creates an urgent need for precise diagnostic and therapeutic tools such as tumor profiling.
In addition, market players are introducing novel tests and kits to provide a deep glance for the researchers, which further accelerates the market growth in the region. For instance, in 2024, Strand Life Sciences launched its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test. This test detects circulating tumor DNA in blood samples of cancer patients to provide a comprehensive analysis of 74 clinically relevant genes, providing invaluable insights for cancer treatment.
The market players in the region are expanding their strategic collaborations and partnerships with the existing market players to expand their businesses and make available the kits with the growing demand. For instance, in October 2024, MGI and OncoDNA collaborated to provide laboratories with a streamlined NGS workflow for implementing the Comprehensive Genomic Profiling (CGP) OncoDEEP Kit in clinical practice.
Cancer Tumor Profiling Market Competitive Landscape
Top companies in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Illumina, Inc., Myriad Genetics, Inc, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Caris Life Sciences., Guardant Health, NanoString Technologies (a Bruker Company), Foundation Medicine, Inc., and Paragon Genomics, Inc., among others.
DMI Insights on Cancer Tumor Profiling Market
According to DMI analysis, the global cancer tumor profiling market size reached US$ 10.98 Billion in 2024 and is expected to reach US$ 24.62 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.
The cancer tumor profiling market is experiencing robust growth globally, driven primarily by the increasing demand for personalized cancer therapies, advances in molecular diagnostics, and expanding applications of next-generation sequencing (NGS) and multi-omics technologies. Tumor profiling, which involves comprehensive molecular characterization of cancer tissue or blood samples, is revolutionizing oncology by enabling tailored treatment plans based on specific genetic, proteomic, and epigenetic alterations.
The market is highly competitive, with key players like Foundation Medicine, Guardant Health, Caris Life Sciences, F. Hoffmann-La Roche Ltd., Illumina, Inc., and others investing heavily in R&D, partnerships, and market expansion. The integration of AI, liquid biopsies, and multi-omics approaches will further enhance the precision and utility of profiling, potentially transforming cancer care globally.
However, overcoming challenges related to cost, data complexity, regulatory harmonization, and equitable access will be critical to unlocking the full potential of tumor profiling. Efforts toward standardization, clinician education, and innovative business models (e.g., tumor profiling as a service) are likely to accelerate market penetration.
The global cancer tumor profiling market report delivers a detailed analysis with 86 key tables, more than 90 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
The global cancer tumor profiling market size reached US$ 10.98 Billion in 2024 from US$ 10.12 Billion in 2023 and is expected to reach US$ 24.62 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.
Cancer Tumor Profiling Market Overview
The cancer tumor profiling market is experiencing significant growth due to advancements in precision medicine, increasing cancer prevalence and the rising demand for personalized treatment approaches. Cancer tumor profiling has revolutionized cancer care by improving diagnosis, treatment efficacy, monitoring and helping to predict patient outcomes.
The market is characterized by strong demand in developed regions, such as North America and Europe, driven by higher healthcare expenditure, advanced healthcare infrastructure and greater adoption of precision medicine. Meanwhile, emerging regions such as Asia-Pacific and Latin America are experiencing increasing adoption of cancer tumor profiling, spurred by growing healthcare investments, increasing cancer rates and expanding awareness about personalized treatment options.
Cancer Tumor Profiling Market Dynamics
Drivers:
The rising prevalence of cancer is significantly driving the cancer tumor profiling market growth
As cancer rates rise globally, there is a growing emphasis on early detection and personalized medicine. Tumor profiling helps identify specific genetic mutations and alterations in tumors, which enables more accurate diagnoses and the development of personalized treatment plans. This helps in providing targeted therapies that are more effective and less toxic than traditional treatments.
For instance, according to the National Institutes of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Additionally, according to the International Agency for Research on Cancer, in 2025, cancer incidence cases are projected to reach 21.3 million, and in 2030, the cases are estimated to reach 24.1 million.
Breast cancer is becoming the most burdensome cancer in the world, with an alarming rise in incidence and prevalence rate. There have been many innovations in the early detection and diagnosis of breast cancer, for which advanced tumor profiling technologies are paving the way. For instance, according to the International Agency for Research on Cancer projections, nearly 2.7 million breast cancer incidence cases are expected to be reported in 2030, rising from 2.3 million in 2022.
As the prevalence of cancer increases, major market players focus on the advancements in next-generation sequencing (NGS) and liquid biopsy technologies that are providing better and more efficient tumor profiling. These advanced technologies, along with artificial intelligence (AI), enable high-throughput testing of genetic mutations in cancer cells, leading to more precise treatment selection.
For instance, in April 2025, Guardant Health, Inc. launched Guardant360 Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, to provide researchers and cancer care teams with a more comprehensive view of cancer. Guardant360 Tissue is built on the smart liquid biopsy platform, which requires 92% less tissue surface area for analysis than the industry norm. The Guardant360 Tissue test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides and thus test more patients using less precious tissue.
Restraints:
The high cost associated with cancer tumor profiling is hampering the growth of the market
High costs make tumor profiling tests inaccessible to a large portion of the population, particularly in low-income regions or among uninsured patients. This limits the potential market for these tests and delays early detection or personalized treatment, which is crucial for improving cancer outcomes.
For instance, according to the National Institutes of Health, turnaround time ranges from 4 days for Oncomine Dx, a 23-gene panel of lung-cancer-related genes, to 21 to 28 days for Ambry Genetics TumorNext, which examines hereditary and somatic mutations in ovarian cancer patients. Costs for testing are in the $3000 to $6000 range. This price point can be prohibitive for many patients, especially those without adequate insurance coverage.
Laboratories that perform tumor profiling using advanced technologies like NGS face high operational costs due to the expensive equipment, consumables and the need for highly skilled personnel. These costs are passed on to healthcare systems and patients, making tumor profiling tests less affordable. For instance, the cost of sequencing equipment for NGS, which includes instruments like the Illumina NovaSeq X Plus, can exceed $1 million. Additionally, reagents and consumables for each test add significant costs to the overall process.
Opportunities:
Integration of artificial intelligence (AI) in tumor profiling creates a market opportunity for the cancer tumor profiling market
Integration of AI in tumor profiling is expected to create a market opportunity for the cancer tumor profiling market, driving advancements in diagnostic accuracy, speed and personalized treatment strategies. AI technologies, including machine learning (ML), deep learning and natural language processing, are transforming the way cancer tumor profiling is conducted by enabling more efficient and precise analyses of large datasets, such as genomic information and medical imaging. Thus, major and emerging market players are focusing on the AI-tumor profiling, gaining market momentum.
For instance, in January 2025, Tempus AI, Inc. launched the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
AI algorithms can process vast amounts of genomic, histopathological and imaging data in a fraction of the time it would take human analysts, reducing errors and ensuring higher diagnostic accuracy. This can significantly improve the effectiveness of tumor profiling, enabling more accurate predictions of cancer behavior and treatment responses.
For instance, New York-based medtech startup Ataraxis AI has emerged from stealth mode, announced $4 million in seed funding. The company has a focus on developing artificial intelligence (AI) driven cancer diagnostics that can help clinicians to pick the best therapy for their patients and predict their progress.
AI-driven platforms can serve as a clinical decision support system, assisting oncologists in interpreting complex tumor profiling results, such as genetic mutations and tumor characteristics. This can lead to more informed clinical decisions and help in identifying optimal treatment paths based on real-time data integration, including genetic profiling, clinical outcomes and patient demographics
Cancer Tumor Profiling Market, Segment Analysis
The global cancer tumor profiling market is segmented based on product type, cancer type, technology type, biomarker type, application, end-user, and region.
The kits and consumables segment from the product type reached US$ 10.11 Billion in 2024 in the cancer tumor profiling market
Kits and consumables include laboratory materials necessary for the execution of tests related to cancer profiling, which could be assay kits, probes, primers, and reagents. These products are necessary for the preparation, processing, and analysis of different tumor samples, whether genomic, proteomic, or metabolomic studies. As the kits are more important products in tumor profiling, market players are launching various kits, which is driving the segment growth.
For instance, in May 2025, Illumina, Inc. received approval from the Ministry of Health, Labour and Welfare (MHLW) for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device) in Japan. TSO Comprehensive is the first FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims in the US. This single test includes analysis of DNA and RNA variants and interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying clinically actionable biomarkers that enable targeted therapy selection or clinical trial enrolment.
Similarly, in October 2024, OncoDNA, a genomic and theranostic company, launched the OncoDEEP Kit, a comprehensive workflow solution for laboratories with NGS capabilities to perform comprehensive biomarker testing, provide powerful data analysis, and support oncologists in personalized treatments for cancer patients.
Cancer Tumor Profiling Market, Geographical Analysis
North America is expected to dominate the global cancer tumor profiling market with a US$ 5.24 Billion in 2024
According to the American Cancer Society, in 2025, 2,041,910 new cancer cases are projected to occur in the United States. The rising cancer cases in North America, especially in the United States, drive demand for personalized treatment strategies, pushing the adoption of tumor profiling to tailor therapies and improve outcomes.
Additionally, although the market is dominant, several market players are actively involved in innovating advanced tumor profiling platforms and launching their products in the region. This will contribute to the further growth of the cancer tumor profiling market in the North American region. For instance, in August 2024, the U.S. Food and Drug Administration (FDA) approved Illumina, Inc.’s in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic indications. This test enables fast matching of patients to targeted therapies.
Asia-Pacific is growing at the fastest pace in the cancer tumor profiling market, holding 18.05% of the market share
APAC is experiencing a rapid increase in cancer cases due to aging populations, urbanization, lifestyle changes, and environmental factors. According to the World Health Organization (WHO), Asia accounts for more than half of global cancer cases, with an expected 10.5 million cases in 2025, with countries like China and India seeing significant year-on-year increases. This escalating cancer burden creates an urgent need for precise diagnostic and therapeutic tools such as tumor profiling.
In addition, market players are introducing novel tests and kits to provide a deep glance for the researchers, which further accelerates the market growth in the region. For instance, in 2024, Strand Life Sciences launched its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test. This test detects circulating tumor DNA in blood samples of cancer patients to provide a comprehensive analysis of 74 clinically relevant genes, providing invaluable insights for cancer treatment.
The market players in the region are expanding their strategic collaborations and partnerships with the existing market players to expand their businesses and make available the kits with the growing demand. For instance, in October 2024, MGI and OncoDNA collaborated to provide laboratories with a streamlined NGS workflow for implementing the Comprehensive Genomic Profiling (CGP) OncoDEEP Kit in clinical practice.
Cancer Tumor Profiling Market Competitive Landscape
Top companies in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Illumina, Inc., Myriad Genetics, Inc, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Caris Life Sciences., Guardant Health, NanoString Technologies (a Bruker Company), Foundation Medicine, Inc., and Paragon Genomics, Inc., among others.
DMI Insights on Cancer Tumor Profiling Market
According to DMI analysis, the global cancer tumor profiling market size reached US$ 10.98 Billion in 2024 and is expected to reach US$ 24.62 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.
The cancer tumor profiling market is experiencing robust growth globally, driven primarily by the increasing demand for personalized cancer therapies, advances in molecular diagnostics, and expanding applications of next-generation sequencing (NGS) and multi-omics technologies. Tumor profiling, which involves comprehensive molecular characterization of cancer tissue or blood samples, is revolutionizing oncology by enabling tailored treatment plans based on specific genetic, proteomic, and epigenetic alterations.
The market is highly competitive, with key players like Foundation Medicine, Guardant Health, Caris Life Sciences, F. Hoffmann-La Roche Ltd., Illumina, Inc., and others investing heavily in R&D, partnerships, and market expansion. The integration of AI, liquid biopsies, and multi-omics approaches will further enhance the precision and utility of profiling, potentially transforming cancer care globally.
However, overcoming challenges related to cost, data complexity, regulatory harmonization, and equitable access will be critical to unlocking the full potential of tumor profiling. Efforts toward standardization, clinician education, and innovative business models (e.g., tumor profiling as a service) are likely to accelerate market penetration.
The global cancer tumor profiling market report delivers a detailed analysis with 86 key tables, more than 90 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Cancer Type
2.5. Snippet by Technology Type
2.6. Snippet by Biomarker Type
2.7. Snippet by Application
2.8. Snippet by End-User
2.9. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer
3.1.1.2. Technological Advancements in Cancer Tumor Profiling
3.1.1.3. Rising Adoption of Personalized and Precision Oncology
3.1.2. Restraints
3.1.2.1. High Cost Associated with Cancer Tumor Profiling
3.1.2.2. Data Privacy and Ethical Concerns
3.1.2.3. Regulatory and Validation Hurdles for Novel Profiling Assays
3.1.3. Opportunity
3.1.3.1. Integration of Artificial Intelligence (AI) in Tumor Profiling
3.1.3.2. Expanding Applications in Rare and Hard-to-Treat Cancers
3.1.3.3. Growth of Immuno-Oncology and Biomarker-Driven Therapies
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Cancer Epidemiology Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. CANCER TUMOR PROFILING MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Kits and Consumables*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Devices
6. CANCER TUMOR PROFILING MARKET, BY CANCER TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Leukemias
6.7. Melanoma Cancer
6.8. Others
7. CANCER TUMOR PROFILING MARKET, BY TECHNOLOGY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassay*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Liquid Biopsy
7.5. Polymerase Chain Reaction
7.6. In-Situ Hybridization
7.7. Microarray
7.8. Others
8. CANCER TUMOR PROFILING MARKET, BY BIOMARKER TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomic Biomarkers*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarkers
8.4. Others
9. CANCER TUMOR PROFILING MARKET, BY APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Clinical Applications*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Diagnostics
9.2.4. Personalized Medicines
9.2.5. Others
9.3. Research Applications
10. CANCER TUMOR PROFILING MARKET, BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Pharmaceutical and Biotechnology Companies
10.5. Research and Educational Institutions
10.6. Others
11. CANCER TUMOR PROFILING MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. U.S.
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. UK
11.3.9.3. France
11.3.9.4. Spain
11.3.9.5. Italy
11.3.9.6. Rest of Europe
11.4. Asia-Pacific
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. China
11.4.9.2. India
11.4.9.3. Japan
11.4.9.4. South Korea
11.4.9.5. Rest of Asia-Pacific
11.5. South America
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. Brazil
11.5.9.2. Argentina
11.5.9.3. Rest of South America
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12.1. Competitive Overview and Key Market Players
12.2. Market Share Analysis and Positioning Matrix
12.3. Strategic Partnerships, Mergers & Acquisitions
12.4. Key Developments in Product Portfolios and Innovations
12.5. Company Benchmarking
13. COMPANY PROFILES
13.1. F. Hoffmann-La Roche Ltd.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.3. Financial Overview
13.1.3.1. Company Revenue
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.2. Mergers & Acquisitions
13.3. Key Product Development Activities
13.4. Regulatory Approvals, etc.
13.5. SWOT Analysis
13.6. Illumina, Inc.
13.7. Myriad Genetics, Inc
13.8. Thermo Fisher Scientific Inc.
13.9. Agilent Technologies, Inc.
13.10. Caris Life Sciences.
13.11. Guardant Health
13.12. NanoString Technologies (a Bruker Company)
13.13. Foundation Medicine, Inc.
13.14. Paragon Genomics, Inc. (LIST NOT EXHAUSTIVE)
14. ASSUMPTIONS AND RESEARCH METHODOLOGY
14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Cancer Type
2.5. Snippet by Technology Type
2.6. Snippet by Biomarker Type
2.7. Snippet by Application
2.8. Snippet by End-User
2.9. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Cancer
3.1.1.2. Technological Advancements in Cancer Tumor Profiling
3.1.1.3. Rising Adoption of Personalized and Precision Oncology
3.1.2. Restraints
3.1.2.1. High Cost Associated with Cancer Tumor Profiling
3.1.2.2. Data Privacy and Ethical Concerns
3.1.2.3. Regulatory and Validation Hurdles for Novel Profiling Assays
3.1.3. Opportunity
3.1.3.1. Integration of Artificial Intelligence (AI) in Tumor Profiling
3.1.3.2. Expanding Applications in Rare and Hard-to-Treat Cancers
3.1.3.3. Growth of Immuno-Oncology and Biomarker-Driven Therapies
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Cancer Epidemiology Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. CANCER TUMOR PROFILING MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Kits and Consumables*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Devices
6. CANCER TUMOR PROFILING MARKET, BY CANCER TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Leukemias
6.7. Melanoma Cancer
6.8. Others
7. CANCER TUMOR PROFILING MARKET, BY TECHNOLOGY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassay*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Liquid Biopsy
7.5. Polymerase Chain Reaction
7.6. In-Situ Hybridization
7.7. Microarray
7.8. Others
8. CANCER TUMOR PROFILING MARKET, BY BIOMARKER TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomic Biomarkers*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarkers
8.4. Others
9. CANCER TUMOR PROFILING MARKET, BY APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Clinical Applications*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Diagnostics
9.2.4. Personalized Medicines
9.2.5. Others
9.3. Research Applications
10. CANCER TUMOR PROFILING MARKET, BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Pharmaceutical and Biotechnology Companies
10.5. Research and Educational Institutions
10.6. Others
11. CANCER TUMOR PROFILING MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. U.S.
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. UK
11.3.9.3. France
11.3.9.4. Spain
11.3.9.5. Italy
11.3.9.6. Rest of Europe
11.4. Asia-Pacific
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. China
11.4.9.2. India
11.4.9.3. Japan
11.4.9.4. South Korea
11.4.9.5. Rest of Asia-Pacific
11.5. South America
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. Brazil
11.5.9.2. Argentina
11.5.9.3. Rest of South America
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12.1. Competitive Overview and Key Market Players
12.2. Market Share Analysis and Positioning Matrix
12.3. Strategic Partnerships, Mergers & Acquisitions
12.4. Key Developments in Product Portfolios and Innovations
12.5. Company Benchmarking
13. COMPANY PROFILES
13.1. F. Hoffmann-La Roche Ltd.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.3. Financial Overview
13.1.3.1. Company Revenue
13.1.3.2. Geographical Revenue Shares
13.1.3.3. Revenue Forecasts
13.1.4. Key Developments
13.2. Mergers & Acquisitions
13.3. Key Product Development Activities
13.4. Regulatory Approvals, etc.
13.5. SWOT Analysis
13.6. Illumina, Inc.
13.7. Myriad Genetics, Inc
13.8. Thermo Fisher Scientific Inc.
13.9. Agilent Technologies, Inc.
13.10. Caris Life Sciences.
13.11. Guardant Health
13.12. NanoString Technologies (a Bruker Company)
13.13. Foundation Medicine, Inc.
13.14. Paragon Genomics, Inc. (LIST NOT EXHAUSTIVE)
14. ASSUMPTIONS AND RESEARCH METHODOLOGY
14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
LIST OF TABLES
Table 1 Global Cancer Tumor Profiling Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Cancer Tumor Profiling Market Value, By Technology Type, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Cancer Tumor Profiling Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Cancer Tumor Profiling Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Cancer Tumor Profiling Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Cancer Tumor Profiling Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 10 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 12 Global Cancer Tumor Profiling Market Value, By Technology Type, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 14 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 16 Global Cancer Tumor Profiling Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 17 Global Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 18 Global Cancer Tumor Profiling Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 19 Global Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Global Cancer Tumor Profiling Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 21 Global Cancer Tumor Profiling Market Value, By Region, 2022-2033 (US$ Billion)
Table 22 North America Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 23 North America Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 24 North America Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 25 North America Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 26 North America Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 27 North America Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 North America Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Europe Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 30 Europe Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 31 Europe Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 32 Europe Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 33 Europe Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 Europe Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 Europe Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Asia-Pacific Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Asia-Pacific Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 38 Asia-Pacific Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 39 Asia-Pacific Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 40 Asia-Pacific Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 41 Asia-Pacific Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 42 Asia-Pacific Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 43 South America Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 44 South America Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 45 South America Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 46 South America Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 47 South America Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 48 South America Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 49 South America Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 50 Middle East and Africa Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 51 Middle East and Africa Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 52 Middle East and Africa Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 53 Middle East and Africa Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 54 Middle East and Africa Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 55 Middle East and Africa Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 56 Middle East and Africa Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 57 F. Hoffmann-La Roche Ltd.: Overview
Table 58 F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 59 F. Hoffmann-La Roche Ltd.: Key Developments
Table 60 Illumina, Inc.: Overview
Table 61 Illumina, Inc.: Product Portfolio
Table 62 Illumina, Inc.: Key Developments
Table 63 Myriad Genetics, Inc.: Overview
Table 64 Myriad Genetics, Inc.: Product Portfolio
Table 65 Myriad Genetics, Inc.: Key Developments
Table 66 Thermo Fisher Scientific Inc.: Overview
Table 67 Thermo Fisher Scientific Inc.: Product Portfolio
Table 68 Thermo Fisher Scientific Inc.: Key Developments
Table 69 Agilent Technologies, Inc.: Overview
Table 70 Agilent Technologies, Inc.: Product Portfolio
Table 71 Agilent Technologies, Inc.: Key Developments
Table 72 Caris Life Sciences.: Overview
Table 73 Caris Life Sciences.: Product Portfolio
Table 74 Caris Life Sciences.: Key Developments
Table 75 Guardant Health: Overview
Table 76 Guardant Health: Product Portfolio
Table 77 Guardant Health: Key Developments
Table 78 NanoString Technologies (a Bruker Company): Overview
Table 79 NanoString Technologies (a Bruker Company): Product Portfolio
Table 80 NanoString Technologies (a Bruker Company): Key Developments
Table 81 Foundation Medicine, Inc.: Overview
Table 82 Foundation Medicine, Inc.: Product Portfolio
Table 83 Foundation Medicine, Inc.: Key Developments
Table 84 Paragon Genomics, Inc.: Overview
Table 85 Paragon Genomics, Inc.: Product Portfolio
Table 86 Paragon Genomics, Inc.: Key Developments
Table 1 Global Cancer Tumor Profiling Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Cancer Tumor Profiling Market Value, By Technology Type, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Cancer Tumor Profiling Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Cancer Tumor Profiling Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Cancer Tumor Profiling Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Cancer Tumor Profiling Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 10 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 12 Global Cancer Tumor Profiling Market Value, By Technology Type, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 14 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 16 Global Cancer Tumor Profiling Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 17 Global Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 18 Global Cancer Tumor Profiling Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 19 Global Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Global Cancer Tumor Profiling Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 21 Global Cancer Tumor Profiling Market Value, By Region, 2022-2033 (US$ Billion)
Table 22 North America Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 23 North America Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 24 North America Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 25 North America Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 26 North America Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 27 North America Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 North America Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Europe Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 30 Europe Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 31 Europe Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 32 Europe Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 33 Europe Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 Europe Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 Europe Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Asia-Pacific Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Asia-Pacific Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 38 Asia-Pacific Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 39 Asia-Pacific Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 40 Asia-Pacific Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 41 Asia-Pacific Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 42 Asia-Pacific Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 43 South America Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 44 South America Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 45 South America Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 46 South America Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 47 South America Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 48 South America Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 49 South America Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 50 Middle East and Africa Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 51 Middle East and Africa Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 52 Middle East and Africa Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)
Table 53 Middle East and Africa Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)
Table 54 Middle East and Africa Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)
Table 55 Middle East and Africa Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)
Table 56 Middle East and Africa Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)
Table 57 F. Hoffmann-La Roche Ltd.: Overview
Table 58 F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 59 F. Hoffmann-La Roche Ltd.: Key Developments
Table 60 Illumina, Inc.: Overview
Table 61 Illumina, Inc.: Product Portfolio
Table 62 Illumina, Inc.: Key Developments
Table 63 Myriad Genetics, Inc.: Overview
Table 64 Myriad Genetics, Inc.: Product Portfolio
Table 65 Myriad Genetics, Inc.: Key Developments
Table 66 Thermo Fisher Scientific Inc.: Overview
Table 67 Thermo Fisher Scientific Inc.: Product Portfolio
Table 68 Thermo Fisher Scientific Inc.: Key Developments
Table 69 Agilent Technologies, Inc.: Overview
Table 70 Agilent Technologies, Inc.: Product Portfolio
Table 71 Agilent Technologies, Inc.: Key Developments
Table 72 Caris Life Sciences.: Overview
Table 73 Caris Life Sciences.: Product Portfolio
Table 74 Caris Life Sciences.: Key Developments
Table 75 Guardant Health: Overview
Table 76 Guardant Health: Product Portfolio
Table 77 Guardant Health: Key Developments
Table 78 NanoString Technologies (a Bruker Company): Overview
Table 79 NanoString Technologies (a Bruker Company): Product Portfolio
Table 80 NanoString Technologies (a Bruker Company): Key Developments
Table 81 Foundation Medicine, Inc.: Overview
Table 82 Foundation Medicine, Inc.: Product Portfolio
Table 83 Foundation Medicine, Inc.: Key Developments
Table 84 Paragon Genomics, Inc.: Overview
Table 85 Paragon Genomics, Inc.: Product Portfolio
Table 86 Paragon Genomics, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 5 Global Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 6 Global Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 7 Global Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 8 Global Cancer Tumor Profiling Market Share, By Region, 2024 & 2033 (%)
Figure 9 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 10 Kits and Consumables Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 11 Devices Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 12 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 13 Breast Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 14 Lung Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 15 Colorectal Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 16 Prostate Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 17 Leukemias Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 18 Melanoma Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Technology Type, 2023-2033 (%)
Figure 21 Immunoassay Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 22 Next-Generation Sequencing Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 23 Liquid Biopsy Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 24 Polymerase Chain Reaction Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 25 In-Situ Hybridization Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 26 Microarray Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 27 Others Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 28 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Biomarker Type, 2023-2033 (%)
Figure 29 Genomic Biomarkers Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 30 Protein Biomarkers Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 31 Others Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 32 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 33 Clinical Applications Application in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 34 Research Applications Application in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 35 Global Cancer Tumor Profiling Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 36 Hospitals End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 37 Diagnostic Centers End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 38 Pharmaceutical and Biotechnology Companies End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 39 Research and Educational Institutions End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 40 Others End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 41 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 42 North America Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 43 North America Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 44 North America Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 45 North America Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 46 North America Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 47 North America Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 48 North America Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 49 North America Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 50 Europe Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 51 Europe Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 Europe Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 53 Europe Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 54 Europe Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 55 Europe Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 56 Europe Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 57 Europe Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 58 Asia-Pacific Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 59 Asia-Pacific Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 60 Asia-Pacific Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 61 Asia-Pacific Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 62 Asia-Pacific Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 63 Asia-Pacific Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 64 Asia-Pacific Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 65 Asia-Pacific Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 66 South America Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 67 South America Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 68 South America Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 69 South America Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 70 South America Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 71 South America Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 72 South America Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 73 South America Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 74 Middle East and Africa Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 75 Middle East and Africa Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 76 Middle East and Africa Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 77 Middle East and Africa Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 78 Middle East and Africa Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 79 Middle East and Africa Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 80 Middle East and Africa Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 81 F. Hoffmann-La Roche Ltd.: Financials
Figure 82 Illumina, Inc.: Financials
Figure 83 Myriad Genetics, Inc.: Financials
Figure 84 Thermo Fisher Scientific Inc.: Financials
Figure 85 Agilent Technologies, Inc.: Financials
Figure 86 Caris Life Sciences.: Financials
Figure 87 Guardant Health: Financials
Figure 88 NanoString Technologies (a Bruker Company): Financials
Figure 89 Foundation Medicine, Inc.: Financials
Figure 90 Paragon Genomics, Inc.: Financials
Figure 1 Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 5 Global Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 6 Global Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 7 Global Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 8 Global Cancer Tumor Profiling Market Share, By Region, 2024 & 2033 (%)
Figure 9 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 10 Kits and Consumables Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 11 Devices Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 12 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 13 Breast Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 14 Lung Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 15 Colorectal Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 16 Prostate Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 17 Leukemias Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 18 Melanoma Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 19 Others Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Technology Type, 2023-2033 (%)
Figure 21 Immunoassay Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 22 Next-Generation Sequencing Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 23 Liquid Biopsy Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 24 Polymerase Chain Reaction Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 25 In-Situ Hybridization Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 26 Microarray Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 27 Others Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 28 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Biomarker Type, 2023-2033 (%)
Figure 29 Genomic Biomarkers Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 30 Protein Biomarkers Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 31 Others Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 32 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 33 Clinical Applications Application in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 34 Research Applications Application in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 35 Global Cancer Tumor Profiling Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 36 Hospitals End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 37 Diagnostic Centers End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 38 Pharmaceutical and Biotechnology Companies End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 39 Research and Educational Institutions End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 40 Others End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 41 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 42 North America Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 43 North America Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 44 North America Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 45 North America Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 46 North America Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 47 North America Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 48 North America Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 49 North America Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 50 Europe Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 51 Europe Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 Europe Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 53 Europe Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 54 Europe Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 55 Europe Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 56 Europe Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 57 Europe Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 58 Asia-Pacific Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 59 Asia-Pacific Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 60 Asia-Pacific Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 61 Asia-Pacific Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 62 Asia-Pacific Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 63 Asia-Pacific Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 64 Asia-Pacific Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 65 Asia-Pacific Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 66 South America Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 67 South America Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 68 South America Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 69 South America Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 70 South America Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 71 South America Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 72 South America Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 73 South America Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)
Figure 74 Middle East and Africa Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)
Figure 75 Middle East and Africa Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)
Figure 76 Middle East and Africa Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 77 Middle East and Africa Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)
Figure 78 Middle East and Africa Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)
Figure 79 Middle East and Africa Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)
Figure 80 Middle East and Africa Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)
Figure 81 F. Hoffmann-La Roche Ltd.: Financials
Figure 82 Illumina, Inc.: Financials
Figure 83 Myriad Genetics, Inc.: Financials
Figure 84 Thermo Fisher Scientific Inc.: Financials
Figure 85 Agilent Technologies, Inc.: Financials
Figure 86 Caris Life Sciences.: Financials
Figure 87 Guardant Health: Financials
Figure 88 NanoString Technologies (a Bruker Company): Financials
Figure 89 Foundation Medicine, Inc.: Financials
Figure 90 Paragon Genomics, Inc.: Financials
